IBIO-600 — IND submission
2026
IND equivalent filing expected in 2026Source filing
IBIO biotech catalysts & pipeline
IBIO INC · Data as of 2026-09-08
Upcoming catalysts
IBIO-610 — IND submission
2H 2026
IBIO-610 IND equivalent filing expected in 2H 2026Source filing
Myostatin x Activin A — IND submission
1H 2027
Myostatin x Activin A IND equivalent filing expected in 1H 2027Source filing
IBIO-600 — Topline data
H2 2027
All four SAD cohorts have been enrolled in this study with 31 participants and each will be monitored for approximately nine months following administration, with study completion expected in second half of 2027.Source filing
IBIO-610 — Conference presentation
Sep 28
The full data will be highlighted in a presentation at the 2026 EASD Annual Meeting, taking place September 28 – October 2 in Milan.Source filing